Follicular lymphoma treatment with subcutaneous bispecific antibody T-cell engager therapy and hematology research
RegulatoryBusiness Wire

AbbVie and Genmab Receive FDA Approval for Epkinly in Follicular Lymphoma

AbbVie and Genmab announce FDA approval of Epkinly (epcoritamab-bysp) for adults with relapsed or refractory follicular lymphoma after two or more prior lines of therapy.

AbbVie and Genmab today announced that the FDA has approved Epkinly (epcoritamab-bysp) for adults with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. Epkinly is a CD20xCD3 bispecific antibody that redirects T cells to kill CD20-positive B-cell lymphoma cells. In the EPCORE NHL-1 trial, Epkinly demonstrated an overall response rate of 82% and a complete response rate of 60% in patients with relapsed or refractory FL. This approval provides patients with relapsed or refractory FL a new subcutaneous bispecific antibody treatment option.

Original Source

Business Wire
Share:

Previous

Novartis Receives FDA Approval for Scemblix as First-Line Treatment for CML

Next

Regeneron Reports Phase 3 EMPOWER-Cervical Results for Libtayo in Cervical Cancer